Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us

Novartis commits $23B to grow US manufacturing capabilities as tariff threat on pharma looms

The news: Novartis is the latest Big Pharma firm to expand its US manufacturing capabilities as the threat of tariffs looms on the sector. The Swiss company will invest $23 billion to build seven new facilities in the US while growing production capacity in three existing manufacturing plants.

Novartis’ pledge to expand US production capacity follows other Big Pharma giants including Johnson & Johnson, Merck, and Eli Lilly that have made similar financial commitments.

The bigger picture: Pharmaceuticals evaded the administration’s first round of levies, but President Trump stated that the industry will soon face “major” tariffs on imports. Notably, most of the ingredients that medicines are made up of are manufactured in China and India.

  • Novartis’ expansion capacity will cover both active pharmaceutical ingredients (API) and biologics drug substance, as well as secondary production and packaging.
  • The company also noted that the new investments will ensure that all “key medicines” for US patients will be able to be produced end-to-end in the US.

The final word: Large pharma companies that have the resources to expand US-based manufacturing can protect themselves against global supply chain disruptions caused by trade wars and pandemics. Generic drugmakers, which supply about 90% of US prescriptions, don’t have the same maneuverability since they sell their products at much lower prices than brand-name medications and have slimmer profit margins.

However, we’ll note that building and expanding manufacturing plants in the US will take years and cost Big Pharma companies billions of dollars—costs that could ultimately be passed onto patients via higher drug prices.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.

You've read 0 of 2 free articles this month.

Create an account for uninterrupted access to select articles.
Create a Free Account